Prognostic Significance of EGFR Gene Amplification and Overexpression in Diffuse Astrocytomas—A Literature Study


Epidermal growth factor receptor (EGFR) has been shown to play an important role in the malignant progression of diffuse astrocytomas. Numerous studies have investigated the clinical significance of overexpression and amplification of the EGFR gene in these tumours with ambiguous results. The aim of this study was therefore to review the literature to get the current prognostic and diagnostic status. The PubMed database was used to search for papers in English in the time period 1987-2010 using the following keywords: astrocytoma, glioma, c-erbB1, EGFR, glioblastoma, HER1 and prognosis. Other inclusion criteria were: 1) studies with more than 50 patients; 2) patient age over 18 years; 3) tumour grading according to the latest World Health Organization (WHO) classification (2007) and 4) EGFR overexpression assessed by immunohistochemistry. A total of 47 publications were included and several reported positive correlations between both EGFR gene amplification and overexpression with histological malignancy grade and survival. The results are, however, encumbered with elements of uncertainty involving for instance methodological diversities and small number of patients. Larger studies with standardized procedures are necessary to fully clarify the clinical role of EGFR in human astrocytomas.

Share and Cite:

K. Winje Hagen and S. Helge Torp, "Prognostic Significance of EGFR Gene Amplification and Overexpression in Diffuse Astrocytomas—A Literature Study," Open Journal of Pathology, Vol. 2 No. 3, 2012, pp. 71-80. doi: 10.4236/ojpathology.2012.23014.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] D. N. Louis, H. Ohgaki, O. D. Wiestler and W. K. Cavenee, “WHO Classification of Tumours of the Central Nervous System,” 4 Edition, IARC, Lyon, 2007.
[2] T. Mitsudomi and Y. Yatabe, “Epidermal Growth Factor Receptor in Relation to Tumor Development: EGFR Gene and Cancer,” FEBS Journal, Vol. 277, No. 2, 2010, pp. 301-308. doi:10.1111/j.1742-4658.2009.07448.x
[3] M. A. Lemmon and J. Schlessinger, “Cell Signaling by Receptor Tyrosine Kinases,” Cell, Vol. 141, No. 7, 2010, pp. 1117-1134. doi:10.1016/j.cell.2010.06.011
[4] B. Coulibaly, I. Nanni, B. Quilichini, J. Gaudart, P. Metellus, F. Fina, C. Boucard, O. Chinot, L. Ouafik and D. Figarella-Branger, “Epidermal Growth Factor Receptor in Glioblastomas: Correlation between Gene Copy Number and Protein Expression,” Human Pathology, Vol. 41, No. 6, 2010, pp. 815-823. doi:10.1016/j.humpath.2009.09.020
[5] J. Schlegel, A. Merdes, G. Stumm, F. K. Albert, M. Forsting, N. Hynes and M. Kiessling, “Amplification of the Epidermal-Growth-Factor-Receptor Gene Correlates with Different Growth Behaviour in Human Glioblastoma,” International Journal of Cancer, Vol. 56, No. 1, 1994, pp. 72-77. doi:10.1002/ijc.2910560114
[6] L. Liu, L. M. Backlund, B. R. Nilsson, D. Grander, K. Ichimura, H. M. Goike and V. P. Collins, “Clinical Significance of EGFR Amplification and the Aberrant EGFRvIII Transcript in Conventionally Treated Astrocytic Gliomas,” Journal of Molecular Medicine, Vol. 83, No. 11, 2005, pp. 917-926. doi:10.1007/s00109-005-0700-2
[7] N. Shinojima, K. Tada, S. Shiraishi, T. Kamiryo, M. Kochi, H. Nakamura, K. Makino, H. Saya, H. Hirano, J. Kuratsu, K. Oka, Y. Ishimaru and Y. Ushio, “Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme,” Cancer Research, Vol. 63, No. 20, 2003, pp. 6962-6970.
[8] H. S. Huang, M. Nagane, C. K. Klingbeil, H. Lin, R. Nishikawa, X. D. Ji, C. M. Huang, G. N. Gill, H. S. Wiley and W. K. Cavenee, “The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling,” Journal of Biological Chemistry, Vol. 272, No. 5, 1997, pp. 2927-2935. doi:10.1074/jbc.272.5.2927
[9] J. R. C. Sainsbury, J. R. Farndon, G. K. Needham, A. J. Malcolm and A. L. Harris, “Epidermal-Growth-Factor Receptor Status as Predictor of Early Recurrence of and Death from Breast-Cancer,” Lancet, Vol. 1, No. 8547, 1987, pp. 1398-1402.
[10] D. E. Neal, C. Marsh, M. K. Bennett, P. D. Abel, R. R. Hall, J. R. Sainsbury and A. L. Harris, “Epidermal-Growth-Factor Receptors in Human Bladder Cancer: Comparison of Invasive and Superficial Tumours,” Lancet, Vol. 1, No. 8425, 1985, pp. 366-368. doi:10.1016/S0140-6736(85)91386-8
[11] S. Ozawa, M. Ueda, N. Ando, N. Shimizu and O. Abe, “Prognostic Significance of Epidermal Growth Factor Receptor in Esophageal Squamous Cell Carcinomas,” Cancer, Vol. 63, No. 11, 1989, pp. 2169-2173. doi:10.1002/1097-0142(19890601)63:11<2169::AID-CNCR2820631117>3.0.CO;2-W
[12] D. Pfeiffer, B. Stellwag, A. Pfeiffer, P. Borlinghaus, W. Meier and P. Scheidel, “Clinical Implications of the Epidermal Growth Factor Receptor in the Squamous Cell Carcinoma of the Uterine Cervix,” Gynecologic Oncology, Vol. 33, No. 2, 1989, pp. 146-150. doi:10.1016/0090-8258(89)90540-4
[13] T. Bauknecht, M. Koler, I. Janz and A. Pfleiderer, “The Occurrence of Epidermal Growth Factor Receptors and the Characterization of EGF-Like Factors in Human Ovarian, Endometrial, Cervical and Breast Cancer. EGF Receptors and Factors in Gynecological Carcinomas,” Journal of Cancer Research and Clinical Oncology, Vol. 115, No. 2, 1989, pp. 193-199. doi:10.1007/BF00397923
[14] M. Van den Eynde, J. F. Baurain, F. Mazzeo and J. P. Machiels, “Epidermal Growth Factor Receptor Targeted Therapies for Solid Tumours,” Acta Clinica Belgica, Vol. 66, No. 1, 2011, pp. 10-17.
[15] J. S. Smith, I. Tachibana, S. M. Passe, B. K. Huntley, T. J. Borell, N. Iturria, J. R. O’Fallon, P. L. Schaefer, B. W. Scheithauer, C. D. James, J. C. Buckner and R. B. Jenkins, “PTEN Mutation, EGFR Amplification, and Outcome in Patients with Anaplastic Astrocytoma and Glioblastoma Multiforme,” Journal of the National Cancer Institute, Vol. 93, No. 16, 2001, pp. 1246-1256. doi:10.1093/jnci/93.16.1246
[16] S. J?rvel?, H. Helin, J. Haapasalo, T. J?rvel?, T. T. Juntila, K. Elenius, M. Tanner, H. Haapasalo and J. Isola, “Amplification of the Epidermal Growth Factor Receptor in Astrocytic Tumours by Chromogenic in Situ Hybridization: Association with Clinicopathological Features and Patient Survival,” Neuropathology and Applied Neurobiology, Vol. 32, No. 4, 2006, pp. 441-450. doi:10.1111/j.1365-2990.2006.00758.x
[17] A. Waha, A. Baumann, H. K. Wolf, R. Fimmers, J. Neumann, D. Kindermann, K. Astrahantseff, I. Blumcke, A. von Deimling and U. Schlegel, “Lack of Prognostic Relevance of Alterations in the Epidermal Growth Factor Receptor-Transforming Growth Factor-Alpha Pathway in Human Astrocytic Gliomas,” Journal of Neurosurgery, Vol. 85, No. 4, 1996, pp. 634-641. doi:10.3171/jns.1996.85.4.0634
[18] U. Diedrich, J. Lucius, E. Baron, J. Behnke, B. Pabst and B. Zoll, “Distribution of Epidermal Growth Factor Receptor Gene Amplification in Brain Tumours and Correlation to Prognosis,” Journal of Neurology, Vol. 242, No. 10, 1995, pp. 683-688. doi:10.1007/BF00866920
[19] J. J. Olson, D. Barnett, J. Yang, R. Assietti, G. Cotsonis and C. D. James, “Gene Amplification as a Prognostic Factor in Primary Brain Tumors,” Clinical Cancer Research, Vol. 4, No. 1, 1998, pp. 215-222.
[20] Y. H. Zhou, F. Tan, K. R. Hess and W. K. Yung, “The Expression of PAX6, PTEN, Vascular Endothelial Growth Factor, and Epidermal Growth Factor Receptor in Gliomas: Relationship to Tumor Grade and Survival,” Clinical Cancer Research, Vol. 9, No. 9, 2003, pp. 3369-3375.
[21] T. T. Batchelor, R. A. Betensky, J. M. Esposito, L. D. Pham, M. V. Dorfman, N. Piscatelli, S. Jhung, D. Rhee and D. N. Louis, “Age-Dependent Prognostic Effects of Genetic Alterations in Glioblastoma,” Clinical Cancer Research, Vol. 10, No. 1, 2004, pp. 228-233. doi:10.1158/1078-0432.CCR-0841-3
[22] A. Korshunov, R. Sycheva and A. Golanov, “The Prognostic Relevance of Molecular Alterations in Glioblastomas for Patients Age < 50 Years,” Cancer, Vol. 104, No. 4, 2005, pp. 825-832. doi:10.1002/cncr.21221
[23] C. Houillier, J. Lejeune, A. Benouaich-Amiel, F. Laigle-Donadey, E. Criniere, K. Mokhtari, J. Thillet, J. Y. Delattre, K. Hoang-Xuan and M. Sanson, “Prognostic Impact of Molecular Markers in a Series of 220 Primary Glioblastomas,” Cancer, Vol. 106, No. 10, 2006, pp. 2218-2223. doi:10.1002/cncr.21819
[24] Y. Ruano, T. Ribalta, A. R. de Lope, Y. Campos-Martin, C. Fiano, E. Perez-Magan, J. L. Hernandez-Moneo, M. Mollejo and B. Melendez, “Worse Outcome in Primary Glioblastoma Multiforme with Concurrent Epidermal Growth Factor Receptor and p53 Alteration,” American Journal of Clinical Pathology, Vol. 131, No. 2, 2009, pp. 257-263. doi:10.1309/AJCP64YBDVCTIRWV
[25] K. D. Aldape, K. Ballman, A. Furth, J. C. Buckner, C. Giannini, P. C. Burger, B. W. Scheithauer, R. B. Jenkins and C. D. James, “Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance,” Journal of Neuropathology and Experimental Neurology, Vol. 63, No. 7, 2004, pp. 700-707.
[26] M. L. Simmons, K. R. Lamborn, M. Takahashi, P. Chen, M. A. Israel, M. S. Berger, T. Godfrey, J. Nigro, M. Prados, S. Chang, F. G. Barker II and K. Aldape, “Analysis of Complex Relationships between Age, p53, Epidermal Growth Factor Receptor, and Survival in Glioblastoma Patients,” Cancer Research, Vol. 61, No. 3, 2001, pp. 1122-1128.
[27] N. G. Rainov, K. U. Dobberstein, H. Bahn, H. J. Holzhausen, C. Lautenschlager, V. Heidecke and W. Burkert, “Prognostic Factors in Malignant Glioma: Influence of the Overexpression of Oncogene and Tumor-Suppressor Gene Products On Survival,” Journal of Neuro-Oncology, Vol. 35, No. 1, 1997, pp. 13-28. doi:10.1023/A:1005841520514
[28] C. Bouvier-Labit, O. Chinot, C. Ochi, D. Gambarelli, H. Dufour and D. Figarella-Branger, “Prognostic Significance of Ki67, p53 and Epidermal Growth Factor Receptor Immunostaining in Human Glioblastomas,” Neuropathology and Applied Neurobiology, Vol. 24, No. 5, 1998, pp. 381-388. doi:10.1046/j.1365-2990.1998.00137.x
[29] A. Chakravarti, M. A. Delaney, E. Noll, P. M. Black, J. S. Loeffler, A. Muzikansky and N. J. Dyson, “Prognostic and Pathologic Significance of Quantitative Protein Expression Profiling in Human Gliomas,” Clinical Cancer Research, Vol. 7, No. 8, 2001, pp. 2387-2395.
[30] A. Chakravarti, W. Seiferheld, X. Tu, H. Wang, H. Z. Zhang, K. K. Ang, E. Hammond, W. Curran Jr. and M. Mehta, “Immunohistochemically Determined Total Epidermal Growth Factor Receptor Levels Not of Prognostic Value in Newly Diagnosed Glioblastoma Multiforme: Report from the Radiation Therapy Oncology Group,” International Journal of Radiation Oncology, Biology, Physics, Vol. 62, No. 2, 2005, pp. 318-327. doi:10.1016/j.ijrobp.2004.10.037
[31] M. C. Etienne, J. L. Formento, C. Lebrun-Frenay, J. Gioanni, M. Chatel, P. Paquis, C. Bernard, A. Courdi, R. J. Bensadoun, J. P. Pignol, M. Francoual, P. Grellier, M. Frenay and G. Milano, “Epidermal Growth Factor Receptor and Labeling Index Are Independent Prognostic Factors in Glial Tumor Outcome,” Clinical Cancer Research, Vol. 4, No. 10, 1998, pp. 2383-2390.
[32] A. B. Heimberger, R. Hlatky, D. Suki, D. Yang, J. Weinberg, M. Gilbert, R. Sawaya and K. Aldape, “Pro- gnostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients,” Clinical Cancer Research, Vol. 11, No. 4, 2005, pp. 1462-1466. doi:10.1158/1078-0432.CCR-04-1737
[33] M. Kogiku, I. Ohsawa, K. Matsumoto, Y. Sugisaki, H. Takahashi, A. Teramoto and S. Ohta, “Prognosis of Glioma Patients by Combined Immunostaining for Survivin, Ki-67 and Epidermal Growth Factor Receptor,” Journal of Clinical Neuroscience, Vol. 15, No. 11, 2008, pp. 1198-1203. doi:10.1016/j.jocn.2007.11.012
[34] P. Korkolopoulou, P. Christodoulou, K. Kouzelis, M. Hadjiyannakis, A. Priftis, G. Stamoulis, A. Seretis and E. Thomas-Tsagli, “MDM2 and p53 Expression in Gliomas: A Multivariate Survival Analysis Including Proliferation Markers and Epidermal Growth Factor Receptor,” British Journal of Cancer, Vol. 75, No. 9, 1997, pp. 1269-1278. doi:10.1038/bjc.1997.216
[35] A. Korshunov, A. Golanov and R. Sycheva, “Immunohistochemical Markers for Prognosis of Cerebral Glioblastomas,” Journal of Neuro-Oncology, Vol. 58, No. 3, 2002, pp. 217-236. doi:10.1023/A:1016218117251
[36] A. Korshunov, A. Golanov, R. Sycheva and I. Pronin, “Prognostic Value of Tumour Associated Antigen Immunoreactivity and Apoptosis in Cerebral Glioblastomas: An Analysis of 168 Cases,” Journal of Clinical Pathology, Vol. 52, No. 8, 1999, pp. 574-580. doi:10.1136/jcp.52.8.574
[37] X. Muracciole, S. Romain, H. Dufour, J. Palmari, O. Chinot, L. Ouafik, F. Grisoli, D. F. Branger and P. M. Martin, “PAI-1 and EGFR Expression in Adult Glioma Tumors: Toward a Molecular Prognostic Classification,” International Journal of Radiation Oncology, Biology, Physics, Vol. 52, No. 3, 2002, pp. 592-598. doi:10.1016/S0360-3016(01)02699-2
[38] E. W. Newcomb, H. Cohen, S. R. Lee, S. K. Bhalla, J. Bloom, R. L. Hayes and D. C. Miller, “Survival of Patients with Glioblastoma Multiforme Is Not Influenced by Altered Expression of p16, p53, EGFR, MDM2 or Bcl-2 Genes,” Brain Pathology, Vol. 8, No. 4, 1998, pp. 655-667. doi:10.1111/j.1750-3639.1998.tb00191.x
[39] T. J. Pigott, D. K. Robson, J. Palmer and L. M. Ward, “Expression of Epidermal Growth Factor Receptor in Human Glioblastoma Multiforme,” British Journal of Neurosurgery, Vol. 7, No. 3, 1993, pp. 261-265. doi:10.3109/02688699309023808
[40] T. Saito, M. T. Arifin, S. Hama, Y. Kajiwara, K. Sugiyama, F. Yamasaki, T. Hidaka, K. Arita and K. Kurisu, “Survivin Subcellular Localization in High-Grade Astrocytomas: Simultaneous Expression in both Nucleus and Cytoplasm Is Negative Prognostic Marker,” Journal of Neuro-Oncology, Vol. 82, No. 2, 2007, pp. 193-198. doi:10.1007/s11060-006-9267-1
[41] C. Sarkar, S. Sinha, M. C. Sharma, R. Kumar and V. S. Mehta, “Supratentorial Glioblastoma in Adults: Identification of Subsets and Their Clinical Correlation,” Brain Tumor Pathology, Vol. 21, No. 1, 2004, pp. 7-12. doi:10.1007/BF02482170
[42] U. Schlegel, J. Neumann, D. Kindermann, H. K. Wolf, A. Baumann, F. Forster and R. Fimmers, “Prognostic Relevance of Transforming Genes,” Recent Results in Cancer Research, Vol. 135, 1994, pp. 43-53. doi:10.1007/978-3-642-85039-4_6
[43] A. M. Stark, H. H. Hugo, P. Witzel, Z. Mihajlovic and H. M. Mehdorn, “Age-Related Expression of p53, Mdm2, EGFR and Msh2 in Glioblastoma Multiforme,” Zentralblatt fur Neurochirurgie, Vol. 64, No. 1, 2003, pp. 30-36. doi:10.1055/s-2003-37149
[44] A. Tortosa, N. Vinolas, S. Villa, E. Verger, J. M. Gil, M. Brell, L. Caral, T. Pujol, J. J. Acebes, T. Ribalta, I. Ferrer and F. Graus, “Prognostic Implication of Clinical, Radiologic, and Pathologic Features in Patients with Anaplastic Gliomas,” Cancer, Vol. 97, No. 4, 2003, pp. 1063-1071. doi:10.1002/cncr.11120
[45] S. Umesh, A. Tandon, V. Santosh, B. Anandh, S. Sampath, B. A. Chandramouli and V. R. S. Kolluri, “Clinical and Immunohistochemical Prognostic Factors in Adult Glioblastoma Patients,” Clinical Neuropathology, Vol. 28, No. 5, 2009, pp. 362-372.
[46] M. Varela, S. M. Ranuncolo, A. Morand, J. Lastiri, E. B. De Kier Joffe, L. I. Puricelli and M. G. Pallotta, “EGF-R and PDGF-R, but Not bcl-2, Overexpression Predict Overall Survival in Patients with Low-Grade Astrocytomas,” Journal of Surgical Oncology, Vol. 86, No. 1, 2004, pp. 34-40. doi:10.1002/jso.20036
[47] M. Wrensch, J. K. Wiencke, J. Wiemels, R. Miike, J. Patoka, M. Moghadassi, A. McMillan, K. T. Kelsey, K. Aldape, K. R. Lamborn, A. T. Parsa, J. D. Sison and M. D. Prados, “Serum IgE, Tumor Epidermal Growth Factor Receptor Expression, and Inherited Polymorphisms Associated with Glioma Survival,” Cancer Research, Vol. 66, No. 8, 2006, pp. 4531-4541. doi:10.1158/0008-5472.CAN-05-4032
[48] A. Zhu, J. Shaeffer, S. Leslie, P. Kolm and A. M. El-Mahdi, “Epidermal Growth Factor Receptor: An Independent Predictor of Survival in Astrocytic Tumors Given Definitive Irradiation,” International Journal of Radiation Oncology, Biology, Physics, Vol. 34, No. 4, 1996, pp. 809-815. doi:10.1016/0360-3016(95)02184-1
[49] C. E. Pelloski, K. V. Ballman, A. F. Furth, L. Zhang, E. Lin, E. P. Sulman, K. Bhat, J. M. McDonald, W. K. Yung, H. Colman, S. Y. Woo, A. B. Heimberger, D. Suki, M. D. Prados, S. M. Chang, F. G. Barker II, J. C. Buckner, C. D. James and K. Aldape, “Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma,” Journal of Clinical Oncology, Vol. 25, No. 16, 2007, pp. 2288-2294. doi:10.1200/JCO.2006.08.0705
[50] S. H. Bigner, P. C. Burger, A. J. Wong, M. H. Werner, S. R. Hamilton, L. H. Muhlbaier, B. Vogelstein and D. D. Bigner, “Gene Amplification in Malignant Human Gliomas: Clinical and Histopathologic Aspects,” Journal of Neuropathology and Experimental Neurology, Vol. 47, No. 3, 1988, pp. 191-205. doi:10.1097/00005072-198805000-00001
[51] E. Galanis, J. Buckner, D. Kimmel, R. Jenkins, B. Alderete, J. O’Fallon, C. H. Wang, B. W. Scheithauer and C. D. James, “Gene Amplification as a Prognostic Factor in Primary and Secondary High-Grade Malignant Gliomas,” International Journal of Oncology, Vol. 13, No. 4, 1998, pp. 717-724.
[52] C. Ang, M. C. Guiot, A. V. Ramanakumar, D. Roberge and P. Kavan, “Clinical Significance of Molecular Biomarkers in Glioblastoma,” Canadian Journal of Neurological Sciences, Vol. 37, No. 5, 2010, pp. 625-630.
[53] L. M. Backlund, B. R. Nilsson, H. M. Goike, E. E. Schmidt, L. Liu, K. Ichimura and V. P. Collins, “Short Postoperative Survival for Glioblastoma Patients with a Dysfunctional Rb1 Pathway in Combination with No Wild-Type PTEN,” Clinical Cancer Research, Vol. 9, No. 11, 2003, pp. 4151-4158.
[54] S. Leenstra, N. T. Oskam, E. H. Bijleveld, D. A. Bosch, D. Troost and T. J. Hulsebos, “Genetic Sub-Types of Human Malignant Astrocytoma Correlate with Survival,” International Journal of Cancer, Vol. 79, No. 2, 1998, pp. 159-165. doi:10.1002/(SICI)1097-0215(19980417)79:2<159::AID-IJC11>3.0.CO;2-5
[55] H. Ohgaki, P. Dessen, B. Jourde, S. Horstmann, T. Nishikawa, P. L. Di Patre, C. Burkhard, D. Schuler, N. M. Probst-Hensch, P. C. Maiorka, N. Baeza, P. Pisani, Y. Yonekawa, M. G. Yasargil, U. M. Lutolf and P. Kleihues, “Genetic Pathways to Glioblastoma: A Population-Based Study,” Cancer Research, Vol. 64, No. 19, 2004, pp. 6892-6899. doi:10.1158/0008-5472.CAN-04-1337
[56] A. L. Quan, G. H. Barnett, S. Y. Lee, M. A. Vogelbaum, S. A. Toms, S. M. Staugaitis, R. A. Prayson, D. M. Peereboom, G. H. Stevens, B. H. Cohen and J. H. Suh, “Epidermal Growth Factor Receptor Amplification Does Not Have Prognostic Significance in Patients with Glioblastoma Multiforme,” International Journal of Radiation Oncology, Biology, Physics, Vol. 63, No. 3, 2005, pp. 695-703. doi:10.1016/j.ijrobp.2005.03.051
[57] M. Weller, J. Felsberg, C. Hartmann, H. Berger, J. P. Steinbach, J. Schramm, M. Westphal, G. Schackert, M. Simon, J. C. Tonn, O. Heese, D. Krex, G. Nikkhah, T. Pietsch, O. Wiestler, G. Reifenberger, A. von Deimling and M. Loeffler, “Molecular Predictors of Progression-Free and Overall Survival in Patients with Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network,” Journal of Clinical Oncology, Vol. 27, No. 34, 2009, pp. 5743-5750. doi:10.1200/JCO.2009.23.0805
[58] M. Jansen, S. Yip and D. N. Louis, “Molecular Pathology in Adult Gliomas: Diagnostic, Prognostic, and Predictive Markers,” Lancet Neurol, Vol. 9, No. 7, 2010, pp. 717-726. doi:10.1016/S1474-4422(10)70105-8
[59] A. von Deimling, K. von Ammon, D. Schoenfeld, O. D. Wiestler, B. R. Seizinger and D. N. Louis, “Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis,” Brain Pathology, Vol. 3, No. 1, 1993, pp. 19-26. doi:10.1111/j.1750-3639.1993.tb00721.x
[60] S. Gulati, B. Ytterhus, U. S. Granli, M. Gulati, S. Lydersen and S. H. Torp, “Overexpression of c-erbB2 Is a Negative Prognostic Factor in Anaplastic Astrocytomas,” Diagnostic Pathology, Vol. 5, 2010, p. 18. doi:10.1186/1746-1596-5-18
[61] S. H. Torp, S. Gulati, E. Johannessen and A. Dalen, “Coexpression of c-erbB 1-4 Receptor Proteins in Human Glioblastomas. An Immunohistochemical Study,” Journal of Experimental and Clinical Cancer Research, Vol. 26, No. 3, 2007, pp. 353-359.
[62] S. H. Torp, E. Helseth, A. Dalen and G. Unsgaard, “Epidermal Growth Factor Receptor Expression in Human Gliomas,” Cancer Immunology, Immunotherapy, Vol. 33, No. 1, 1991, pp. 61-64. doi:10.1007/BF01742530
[63] M. H. Werner, L. B. Nanney, C. M. Stoscheck and L. E. King, “Localization of Immunoreactive Epidermal Growth Factor Receptors in Human Nervous System,” Journal of Histochemistry and Cytochemistry, Vol. 36, No. 1, 1988, pp. 81-86. doi:10.1177/36.1.3275713
[64] S. Robel, B. Berninger and M. Gotz, “The Stem Cell Potential of Glia: Lessons from Reactive Gliosis,” Nature Reviews Neuroscience, Vol. 12, No. 2, 2011, pp. 88-104. doi:10.1038/nrn2978
[65] F. Burel-Vandenbos, M. Benchetrit, C. Miquel, D. Fontaine, R. Auvergne, C. Lebrun-Frenay, N. Cardot-Leccia, J. F. Michiels, V. Paquis-Flucklinger and T. Virolle, “EGFR Immunolabeling Pattern May Discriminate Low-Grade Gliomas from Gliosis,” Journal of Neuro-Oncology, Vol. 102, No. 2, 2011, pp. 171-178. doi:10.1007/s11060-010-0308-4
[66] K. S. Yoon, M. C. Lee, S. S. Kang, J. H. Kim, S. Jung, Y. J. Kim, J. H. Lee, K. Y. Ahn, J. S. Lee and J. Y. Cheon, “p53 Mutation and Epidermal Growth Factor Receptor Overexpression in Glioblastoma,” Journal of Korean Medical Science, Vol. 16, No. 4, 2001, pp. 481-488.
[67] H. K. Gan, A. H. Kaye and R. B. Luwor, “The EGFRvIII Variant in Glioblastoma Multiforme,” Journal of Clinical Neuroscience, Vol. 16, No. 6, 2009, pp. 748-754. doi:10.1016/j.jocn.2008.12.005
[68] I. K. Mellinghoff, M. Y. Wang, I. Vivanco, D. A. Haas-Kogan, S. Zhu, E. Q. Dia, K. V. Lu, K. Yoshimoto, J. H. Huang, D. J. Chute, B. L. Riggs, S. Horvath, L. M. Liau, W. K. Cavenee, P. N. Rao, R. Beroukhim, T. C. Peck, J. C. Lee, W. R. Sellers, D. Stokoe, M. Prados, T. F. Cloughesy, C. L. Sawyers and P. S. Mischel, “Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors,” New England Journal of Medicine, Vol. 353, No. 19, 2005, pp. 2012-2024. doi:10.1056/NEJMoa051918
[69] C. J. Wikstrand, R. E. McLendon, A. H. Friedman and D. D. Bigner, “Cell Surface Localization and Density of the Tumor-Associated Variant of the Epidermal Growth Factor Receptor, EGFRvIII,” Cancer Research, Vol. 57, No. 18, 1997, pp. 4130-4140.
[70] L. Ohman, L. Gedda, G. Hesselager, R. Larsson, M. Nister, T. Stigbrand, K. Wester and J. Carlsson, “A New Antibody Recognizing the vIII Mutation of Human Epidermal Growth Factor Receptor,” Tumour Biology, Vol. 23, No. 2, 2002, pp. 61-69. doi:10.1159/000059704
[71] Y. H. Zhou, K. R. Hess, V. R. Raj, L. Yu, L. Liu, A. W. Yung and M. E. Linskey, “Establishment of Prognostic Models for Astrocytic and Oligodendroglial Brain Tumors with Standardized Quantification of Marker Gene Expression and Clinical Variables,” Biomark Insights, Vol. 5, 2010, pp. 153-168. doi:10.4137/BMI.S6167

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.